‘Life-threatening complications!’ Ozempic warning as 82 deaths and 400 hospitalisations linked to weight loss jabs
An urgent health warning has been issued after 82 deaths in the UK were linked to weight-loss and diabetes drugs such as Ozempic and Mounjaro.
The Medicines and Healthcare products Regulatory Agency (MHRA) reported at least 22 fatalities connected to weight-loss medication up to the end of January.
A further 60 deaths were recorded for products used to treat Type 2 diabetes. Nearly 400 people have required hospital treatment since these products were rolled out.
The NHS warns patients to “never take an anti-obesity medicine if it has not been prescribed to you”.
Figures from the MHRA reveal that 18 deaths were linked to Mounjaro, which was recently approved for NHS use, The Sun has revealed.
A further 29 fatalities occurred in patients taking Ozempic, Rybelsus or Wegovy, which contain the active ingredient semaglutide.
The highest death toll was associated with Saxenda and Victoza, with 35 reported fatalities.
These medications are currently taken by an estimated half a million people across the UK.
MORE LIKE THIS:
- Ozempic: ‘Alarming’ side effect warning as health expert outlines biggest risk factor
- Andrew and Bev left astounded as guest shares horrifying experience with Ozempic: ‘Extraordinary!’
- Benefits crackdown to see obese Britons offered FREE Ozempic weight-loss drug
The warning comes six months after a Scottish nurse became the first person in Britain whose death was directly linked to a weight-loss jab.
Susan McGowan, 58, died at University Hospital Monklands in Airdrie on September 4 after suffering multiple organ failure, septic shock and pancreatitis.
She had taken two low-dose injections of Mounjaro, also known as tirzepatide, which she purchased from an online pharmacy.
Reported side effects of these medications include nausea, vomiting and diarrhoea.
Some doctors have warned of “life-threatening complications” such as seizures or bowel obstruction.
Currently, these drugs can be obtained from major chemists by completing an online form with weight and height details and submitting photographs.
The Society for Acute Medicine has joined other experts in calling for stricter controls on how these weight-loss products are prescribed.
Dr Alison Cave, MHRA chief safety officer, said: “The decision to start, continue or stop treatments should be made jointly by patients and their doctor, based on full consideration of benefits and risks.”
A spokesman for Lilly UK, which manufactures Mounjaro, stated that patient safety is their “top priority”.
The company added: “Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine and Lilly is committed to continually monitoring, evaluating, and reporting safety data.”
The MHRA has emphasised that healthcare professionals must advise whether these medications are necessary for patients.
Patients can currently access these drugs through major pharmacy chains by completing online forms and providing photographs.
Medical organisations, including the Society for Acute Medicine, are now calling for tighter restrictions on how Ozempic, Mounjaro and other weight-loss products are prescribed.
Anyone experiencing side effects while taking these medications is advised to consult their doctor or healthcare professional.